Giant Biogene (02367.HK) Hong Kong Hot Stock Analysis

Giant Biogene (02367.HK) is a leading biotech company in the field of recombinant collagen technology in China, founded in 2000 by Professor Fan Daidi, a pioneer in this field [6]. In November 2022, the company became the first “recombinant collagen concept stock” on the main board of the Hong Kong Stock Exchange [6]. Its core business covers three segments: functional skincare products, medical devices, and functional food/special medical purpose formula food, with 8 core brands including Keyi Mei, Keyi Jin, Keyi Yu, and Keyi Hen [6][7]. In terms of key technologies, the company has proprietary recombinant collagen technology, which can produce collagen with a purity of 99.9% and an amino acid sequence 100% consistent with human collagen. It also masters synthetic biology methods to mass-produce 5 rare saponins (Rk3, Rh4, Rk1, Rg5, CK) [6][8]. Recent developments include: from December 9 to 11, 2025, the company repurchased a total of 1.2 million shares, with a total amount of approximately HK$42.6464 million, which is part of the plan to repurchase no more than 10% of the issued shares [3][9]; in October 2025, the company’s first Class III medical device - recombinant collagen facial wrinkle correction injection was approved, marking an important milestone in the expansion of its medical beauty business [7].

1. As a leader in recombinant collagen technology, the company has technical barriers and brand advantages in the segmented field. Its 8 core brands cover multiple application scenarios, with outstanding market influence.
2. The approval of Class III medical devices is an important breakthrough in the company’s business expansion, which will bring new growth momentum to its medical beauty segment.
3. The continuous share repurchase plan shows the company’s management’s recognition of its own value, which helps to boost market confidence.

• Opportunities
  : The demand for recombinant collagen market continues to grow, and the company’s technical and brand advantages provide support for its expansion in functional skincare products, medical devices and other fields; the approval of Class III medical devices will further expand its business boundaries.
• Risks
  : Industry competition may intensify, requiring continuous R&D investment to maintain technical leading advantages; there is uncertainty about the market’s acceptance of new products.

Giant Biogene (02367.HK) occupies an important position in the biotech field with its core recombinant collagen technology and multi-brand strategy. The recent share repurchases and the approval of Class III medical devices are important milestones in the company’s development, laying the foundation for its future growth.